Innovative lipid-modifying agents are valuable resources to improve the control of atherogenic dyslipidemias and reduce the lipid-related residual cardiovascular risk of patients with intolerance or who are not fully responsive to a consolidated standard of care (statins plus ezetimibe). Moreover, some of the upcoming compounds potently affect lipid targets that are thus far considered "unmodifiable". The present paper is a viewpoint aimed at presenting the incremental metabolic and cardiovascular benefits of the emerging lipid-modulating agents and real-life barriers, hindering their prescription by physicians and their assumption by patients, which need to be worked out for a more diffuse and appropriate drug utilization.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963828 | PMC |
| http://dx.doi.org/10.3390/ph16020176 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of seeds on Glycated hemoglobin, Cardiovascular disease risks and dyslipidemia in Type-2 diabetic patients in Karachi: A non-blind randomized controlled trial.
Pak J Med Sci
January 2025
Sadia Anwer Research Student, Biochemistry, Federal Urdu University of Arts, Science & Technology, Karachi, Pakistan.
Objective: To explore the effect of seeds powder { 500 mg} capsule in diabetes Type-2 (T2DM) patients in Karachi.
Methods: A randomized selection of 40 T2DM patients from Sindh Government Hospital New Karachi with their consents was done for a non-blinded controlled trial from October to December 2019 and divided into P (Positive Control, metformin 500 mg) & T (Test, + was also included, using the same dosage of CapCASP on twenty healthy volunteers. The data were analyzed using an online graph pad student's t-test and a one-way ANOVA (SPSS version 24) metformin 500mg each).
Submicron Dispersions of Phytosterols Reverse Liver Steatosis with Higher Efficacy than Phytosterol Esters in a Diet Induced-Fatty Liver Murine Model.
Int J Mol Sci
January 2025
Department of Nutrition, Faculty of Medicine, University of Chile, Santiago 8380000, Chile.
Consumption of phytosterols is a nutritional strategy employed to reduce cholesterol absorption, but recent research shows that their biological activity might go beyond cholesterol reduction for the treatment of metabolic dysfunction-associated fatty liver disease (MAFLD), and novel phytosterol formulations, such as submicron dispersions, could improve these effects. We explored the therapeutic activity of phytosterols, either formulated as submicron dispersions of phytosterols (SDPs) or conventional phytosterol esters (PEs), in a mouse model of MAFLD. MAFLD was induced in mice by atherogenic diet (AD) feeding.
View Article and Find Full Text PDFThe association between radiographic progression, functional impairment, markers of dyslipidaemia and inflammation in patients with hand osteoarthritis: a five-year longitudinal study.
Clin Exp Rheumatol
January 2025
Institute of Rheumatology, and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
Objectives: This study aimed to investigate the associations between radiographic damage, serum biomarkers, and clinical assessments in Czech patients with hand osteoarthritis (HOA) over a five-year follow-up period.
Methods: The study cohort comprised 129 patients diagnosed with HOA, including 72 patients with an erosive subtype and 57 patients with a non-erosive subtype. Radiographs were evaluated using the Kallman scoring system by two independent readers.
Overweight, obesity, and cardiovascular disease in heterozygous familial hypercholesterolaemia: the EAS FH Studies Collaboration registry.
Eur Heart J
January 2025
Department of Primary Care and Public Health, Imperial Centre for Cardiovascular Disease Prevention, School of Public Health, Imperial College London, White City Campus, 90 Wood Lane, London W12 0BZ, UK.
Background And Aims: Overweight and obesity are modifiable risk factors for atherosclerotic cardiovascular disease (ASCVD) in the general population, but their prevalence in individuals with heterozygous familial hypercholesterolaemia (HeFH) and whether they confer additional risk of ASCVD independent of LDL cholesterol (LDL-C) remains unclear.
Methods: Cross-sectional analysis was conducted in 35 540 patients with HeFH across 50 countries, in the EAS FH Studies Collaboration registry. Prevalence of World Health Organization-defined body mass index categories was investigated in adults (n = 29 265) and children/adolescents (n = 6275); and their association with prevalent ASCVD.
Exploring emerging pharmacotherapies for type 2 diabetes patients with hypertriglyceridemia.
Expert Opin Pharmacother
January 2025
Division of Cardiology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei City, Taiwan.
Introduction: Atherogenic dyslipidaemia with increased triglycerides, low high-density lipoprotein cholesterol levels and increased small dense low-density lipoprotein (LDL) particles is a major risk factor contributing to the increased cardiovascular (CV) risk in patients with type 2 diabetes (T2D). This is regarded as a residual risk after achieving target levels of LDL cholesterol.
Areas Covered: This article reviews the novel therapies to reduce triglycerides in patients with T2D.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!